Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

B SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing…
posteditor
posteditor
Articles: 21727

Other News